GENESIS (NCT 03246529) is a 2-part, Phase-3, randomized, double-blind, placebo-controlled, multicenter study evaluating the safety and efficacy of APHEXDA (motixafortide) plus filgrastim (G-CSF), ...

Successful autologous hematopoietic stem cell transplant (ASCT) requires a sufficient number of stem cells from peripheral blood to be collected. In many cases, stem cell collection may be difficult ...

The UCSC STEM Postdoc Symposium on Wednesday, April 24, will include a public reception featuring poster presentations by early career scientists at UC Santa Cruz. The event will take place from 5 to ...

-- Poster presentation of MGTA-145 investigator-initiated Phase 2 clinical trial data confirmed previously reported positive topline clinical data for stem cell mobilization and transplant in multiple ...

Individuals will be notified before the event if their poster has been accepted for presentation. NOTE: If your abstract is accepted, you will be asked to be available at your poster during half of ...

Stem cell scientists earn recognition for their research at ISSCR's International Symposium this month in Athens, Greece. Pictured left to right: Alice Rossi, PhD, Angeliki Spathopoulou, PhD, and ...

NATICK, Mass. -- The 13th Annual Future Workforce Poster Presentation took place at the U.S. Army Combat Capabilities Development Command Soldier Center on August 15. The event showcased the CCDC ...

Nachrichten»BioLineRx Ltd.: BioLineRx Announces Acceptance of Two Poster Presentations on APHEXDA (motixafortide) for CD34+ Hematopoietic Stem Cell (HSC) Mobilization in Patients with Multiple Myeloma ...

Poster presentations may not seem as prestigious as oral presentations, but they are a great opportunity to interact with other scientists in your field in a reasonably structured way. Just like oral ...